INTRODUCTION
============

Translocation of chromosome 21q22 resulting in alterations of the Runt-related transcription factor 1 (*RUNX1*) gene commonly occurs in hematologic malignancies. The *RUNX1* gene (known as *AML-1*, *CBFA2*, or *PEBP2αB*) encodes the α-subunit of core *binding factor* (CBFα) which forms heterodimer with core-binding factor-β (CBFβ) and plays a key role in the initiation of hematopoiesis and the generation of hematopoietic stem cells in the embryo ([@B1],[@B2]). The *RUNX1* gene was first identified as a fusion partner in the t(8;21) (q22;q22) in AML-M2 ([@B3]). To date, 39 sites of recurrent translocation have been described in hematologic malignancies, and a minimum of 19 partner genes have been identified at the molecular level ([@B4]).

*HOX* genes were first identified as essential factors for the regulation of limb positioning during embryogenesis ([@B5]). The *HOX* gene family, which encodes DNA-binding transcription factors, consists of 39 *HOX* genes arranged into 4 gene clusters (A, B, C, and D) located on 4 different chromosomes, 7p15, 17q21, 12q13 and 2q31, respectively. *HOX* A, B, and C clustered genes are expressed during early hematopoiesis of hematopoietic stem cells and progenitors, and are downregulated during the later stages of differentiation and maturation of hematopoietic progenitors ([@B6]). It has been reported that dysregulation of *HOX* genes could have an impact on leukemic development ([@B7],[@B8]). The NUP98-HOXA9 fusion protein has been demonstrated to play a role in leukemogenesis ([@B9]), which indicates that translocation and fusion protein generation could be a mechanism responsible for altered *HOX* gene function.

The current case, to the best of our knowledge, is the first report demonstrating juxtaposition of *HOXA* and *RUNX* via reciprocal translocation, t(7;21)(p15;q22), in AML.

MATERIALS AND METHODS
=====================

Case summary
------------

A sample of bone marrow aspirate from a 57-year-old woman with a presumptive diagnosis of AML was submitted for karyotype analysis and fluorescence *in situ* hybridization (FISH). She had been diagnosed with chronic idiopathic myelofibrosis 39 months prior to this presentation. The complete blood count (CBC) indicated the following: Hb 75 g/L; platelet count 41×10^9^/L; and leukocyte count 50.6×10^9^/L with 10% neutrophils, 59% lymphocytes, 2% metamyelocytes, and 29% blasts. Bone marrow aspirate smears showed 100% cellularity with 67% blasts which consisted of moderate-sized to-large cells showing high nuclear/cytoplasmic ratios, fine nuclear chromatin, and prominent nucleoli, but no definite Auer rods. Immunophenotype analysis revealed that leukemic cells were strongly positive for HLA-DR, CD34, CD13, CD33, CD117, and myeloperoxidase.

Cytogenetic analysis
--------------------

Conventional cytogenetic analysis was performed in bone marrow cells by using unstimulated 24-h culture method and G-banding. The karyotype was described according to the guidelines of International System for Human Cytogenetic Nomenclature (ISCN) 2009.

Fluorescence *in situ* hybridization (FISH)
-------------------------------------------

To evaluate the status of *RUNX1* on 21q22, FISH was performed with a commercial LSI AML1/ETO Dual Color, Dual Fusion Translocation Probe (Vysis, Downers Grove, IL). To investigate the breakpoint on the short arm of chromosome 7 inducing the t(7;21), FISH was performed with \"in-house\" dual color break-apart BAC probes designed to target the specific sites of *HOXA*-clustered genes on chromosome 7p15. Eight BAC clones specific for the *HOXA* genes were selected from the human genome browser database Genome Bioinformatics Group, University of California, Santa Cruz (<http://genome.ucsc.edu/>) ([Fig. 2A](#F2){ref-type="fig"}); 3 clones (RP11-838G2, RP11-1080K8 and RP11-627P22) and 2 clones (RP11-1148E13 and RP11-299F5) targeting the telomeric and centromeric side of the *HOXA* gene cluster, respectively, and the remaining 3 clones (RP11-163M21, RP11-1132K14, and RP11-1025G19) alternatively encompassing the *HOXA* genes. After bacterial culture, plasmid DNA was purified using the plasmid DNA purification kit (Qiagen Sciences, Germantown, MD), and labeled by nick-translation (Nick Translation Kit; Abbott Molecular Inc., North Chicago, IL). FISH with \"in house\" BAC probes was performed as previously reported ([@B10]). Briefly, probe signals were enumerated from 200 interphase cells. A cutoff for a true positive break apart signal was set at \>5% of interphase cells showing separation of red and green signals at a level greater than twice the usual signals. All probes were verified for the expected site of hybridization by using normal lymphocyte metaphases (data not shown).

RESULTS
=======

Cytogenetic analysis
--------------------

The G-banded karyotype demonstrated 46,XX,t(7;21)(p15;q22) ([Fig. 1A](#F1){ref-type="fig"}).

FISH
----

Interphase FISH using the LSI AML1/ETO probes showed 1 large and 2 small green signals, and 2 red signals in \~50% of the nuclei. Metaphase FISH analysis demonstrated 1 large green signal on the intact chromosome 21 and 2 small green signals on the derivative chromosome 7 as well as on derivative chromosome 21 ([Fig. 1B](#F1){ref-type="fig"}). These results indicate that 1 *RUNX1* gene split and translocated to a position other than the *ETO* gene, which is consistent with the results of cytogenetic analysis, that is, t(7;21)(p15;q22).

Five pairs of break-apart probe sets targeting the *HOXA* gene cluster were applied to normal control slides and patient bone marrow slides. Every probe set showed fusion or closely paired signals in normal lymphocytes, whereas the patient slides revealed fusion or separated signals depending on the probe set combinations. FISH using probe set 1 (RP11-838G2, RP11-1148E13), probe set 2 (RP11-1080K8, RP11-299F5), and probe set 3 (RP11-163M21, RP11-1148E13) demonstrated 1 closely paired red-green fusion signal on the normal chromosome 7, but 1 red signal on the derivative chromosome 21 and 1 green signal on the derivative chromosome 7 in the metaphase cells ([Fig. 2B](#F2){ref-type="fig"}). These observations indicate that the break point is within the *HOXA* gene. One fusion, 1 red, and 1 green signals were found in \~35% of the interphase cells. FISH using probe set 4 (RP11-838G2, RP11-1025G19) and probe set 5 (RP11-627P22, RP11-1132K14) showed 1 fusion signal each on the normal chromosome 7 and the derivative chromosome 21, and 1 small green signal on the derivative chromosome 7 in the patient metaphase cells ([Fig. 2C](#F2){ref-type="fig"}). These results indicate that the break point is located in the region covered by both RP11-1025G19 and RP11-1132K14 probes. Interphase FISH showed the same signal pattern in 30% of the bone marrow cells. Taken together, these results narrow down the break point to within 50 kb of the region comprising *HOXA* 9-13 genes ([Fig. 2A](#F2){ref-type="fig"}).

DISCUSSION
==========

A novel translocation of *RUNX1* to the *HOXA* gene cluster in an AML patient with 46,XX,t(7;21)(p15;q22) was identified, which implies that *HOXA* and *RUNX1* could be reciprocal translocational gene partners.

These cases of AML with t(7;21)(p15;q22) has been reported: 1 case with a single translocation and the other 2 cases with complex chromosomal aberrations ([@B11],[@B12]). More than 30 cancer-associated candidate genes, including the *HOXA* gene cluster, have been identified on chromosome 7p15 ([@B4]). However, the identity of the gene on the 7p15 section of the chromosome that is the translocation partner of *RUNX1* remains unclear.

*HOXA* cluster genes play an important role in homeostatic hematopoiesis, and their deregulation can induce leukemic transformation ([@B6]-[@B8]). Several mechanisms have been suggested for *HOX* gene deregulation as a single or co-operative factor in leukemogenic function ([@B8],[@B13]). *NUP98-HOXA9* gene expression is leukemogenic in mice ([@B7]) and is detected in human AML cells ([@B9],[@B14]). These reports show that translocation and fusion protein generation could be a mechanism underlying *HOX* gene deregulation. No reports of a translocational partnership between the *HOXA* gene cluster and *RUNX1* have been published to date.

The current data show a definite reciprocal translocation between *RUNX1* and the *HOXA* gene cluster. FISH data with a BAC clone probe set combination localized the gene fusion site to a 50-kb region, which comprises *HOXA9*, *HOXA10*, *HOXA11*, and *HOXA13* ([Fig. 2A](#F2){ref-type="fig"}). Considering frequently occurring break points within both genes as well as the current data, possible translocational fusion genes, including *RUNX1-HOXA9*, *RUNX1-HOXA10*, *RUNX1-HOXA11* , and *RUNX1-HOXA13*, can be postulated ([Fig. 2D](#F2){ref-type="fig"}).

Efficient functioning of the transcription factor CBFα, encoded by *RUNX1*, normally requires its heterodimeric partner CBFβ which promotes DNA binding of CBFα ([@B15]). AML1-ETO, the prototype *RUNX1* fusion gene product, functions as a dominant-negative transcription factor on CBFα target genes ([@B16]). NUP98-*HOXA9* fusion protein binds to DNA via the homeodomain of *HOXA9* and is thought to function as a transcription factor ([@B8],[@B9],[@B14]). The case under study did not show any other translocation except t(7;21)(p15;q22)/*RUNX1-HOXA* gene cluster, and all possible fusion genes *HOXA(9-13)* may be equally responsible for homeodomain formation. Taken together, these observations suggest that t(7;21)(p15;q22)/*RUNX1-HOXA*(9-13) may play a causative role in leukemic development in the patient under study.

Studies with animal models have demonstrated that artificially induced overexpression of *HOX* genes, including *HOXA9*, *HOXA10*, and *NUP98-HOXA9*, gave rise to myeloproliferative diseases, which then progressed to AML with long-latency periods ([@B7],[@B17]). Secondary AML from myelofibrosis was fatal except 2 cases showing favorable cytogenetic abnormalities, t(8;21) and inv(16) ([@B18]). However, the exact role of the involved genes remains unclear. The present case was secondary AML from chronic myelofibrosis at an interval of 39 months. Unfortunately, it is unclear whether t(7;21) (p15;q22)/*RUNX1-HOXA* in the present case was associated with the early developmental stage of myeloproliferative neoplasms or with the late stage progression to secondary AML because the initial bone marrow sample was inadequate for cytogenetic studies, similar to most myelofibrotic bone marrow samples. Further identification of fusion gene products or direct sequencing of the fusion gene was not performed because of limited bone marrow samples.

In summary, this study described a rare translocation of t(7;21)(p15;q22) and the first identification of *RUNX1-HOXA* fusion gene involvement in AML, diagnosed secondary to myelofibrosis, which suggests the possibility that *RUNX1* and *HOXA* genes could be reciprocal translocation partners and may play a role in leukemogenesis.

This work was supported by a Terry Fox Program Project Award, the Leukemia Lymphoma Society of Canada and the British Columbia Cancer Foundation.

The authors have no financial conflict of interest.

*RUNX*

:   Runt-related transcription factor

AML

:   acute myeloid leukemia

*HOXA*

:   Homeobox A

CBF

:   core binding factor

![(A) Representative metaphase G-banding of the patient bone marrow aspirate showing 46,XX, t(7;21)(p22;q22). (B) Metaphase fluorescence *in situ* hybridization analysis using *AML1/ETO* dual-color, dual-fusion translocation probes demonstrate translocation of *RUNX1* into chromosome 7; 2 usual-sized red signals on 2 intact chromosome 8, 1 usual-sized green signal on chromosome 21 (arrow), and tw1 small green signal each on derivative chromosome 21 (arrowhead) and derivative chromosome 7 (dotted arrow).](in-13-222-g001){#F1}

![(A) BAC clone probes designed and *HOXA* gene clusters on chromosome 7p15.2. The arrow between the dotted and solid lines represents the break point area. (B) Metaphase FISH using the probe set RP11-163M21 and RP11-1148E13 showing translocation of the gene segment, including *HOXA1-7*, to derivative chromosome 21. (C) Metaphase FISH using probe set RP11-838G2 and RP11-1025G19 showing translocation of the gene segment, including a part of *HOXA 9-13*, to derivative chromosome 21. (D) Putative fusion gene map of t(7;21): *RUNX1/HOXA9-13*.](in-13-222-g002){#F2}
